An Open-Label Study of Oral CEP-701 in Patients With Polycythaemia Vera or Essential Thrombocytosis With the JAK2 V617F Mutation

Trial Profile

An Open-Label Study of Oral CEP-701 in Patients With Polycythaemia Vera or Essential Thrombocytosis With the JAK2 V617F Mutation

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Oct 2015

At a glance

  • Drugs Lestaurtinib (Primary)
  • Indications Polycythaemia vera; Thrombocytosis
  • Focus Pharmacodynamics
  • Sponsors Cephalon
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 15 Aug 2014 New trial record
    • 23 Aug 2011
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top